Selonsertib misses endpoint, provides future trial design insight

BOSTON — While selonsertib did not demonstrate efficacy as a monotherapy in patients with nonalcoholic steatohepatitis-related advanced fibrosis, data from the trial provided key insights for future trial design and potential for selonsertib in combination therapy, according to data presented at The Liver Meeting 2019.“It’s important to see what we can glean from a study of this magnitude,” Stephen A. Harrison, MD, medical director of Pinnacle Clinical Research in San Antonio, said during his presentation. “Data from these trials provide important informationRead More

Share on facebook
Share on twitter
Share on linkedin